SETP2 Lymphoid Malignancies

[OS1-7B-5] Allogeneic hematopoietic stem cell transplantation for patients with aggressive NK cell leukemia

Ayumi Fujimoto¹, Fumihiro Ishida^2,8, Koji Izutsu³, Satoshi Yamasaki⁴, Dai Chihara⁵, Junji Suzumiya¹, Tetsuo Mitsui⁶, Kazuteru Ohashi⁷, Hideyuki Nakazawa⁸, Hikaru Kobayashi⁹, Junya Kanda¹⁰, Takahiro Fukuda¹¹, Yoshiko Atsuta¹², Ritsuro Suzuki¹ (1.Oncology and Hematology, Shimane University Hospital, Izumo, Japan, 2.Biomedical Laboratory Sciences, Shinshu University School of Medicine, Matsumoto, Japan, 3.Hematology, National Cancer Center Hospital, Tokyo, Japan, 4.Hematology and Clinical Research Institute, Kyushu Medical Center, Fukuoka, Japan, 5.Center for Cancer Research National Cancer Institute, Bethesda, MD, USA, 6.Pediatrics, Yamagata University School of Medicine, Yamagata, Japan, 7.Hematology, Komagome Hospital, Tokyo, Japan, 8.Hematology, Shinshu University School of Medicine, Matsumoto, Japan, 9.Hematology, Nagano Red Cross Hospital, Nagano, Japan, 10.Hematology and Oncology, Kyoto University, Kyoto, Japan, 11.Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan, 12.Japanese Data Center for Hematopoietic Cell Transplantation)